196 related articles for article (PubMed ID: 35693282)
1. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
3. Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
He Z; Zhou H; Wang J; Li D; Zhang X; Wang P; Ma T; Zhang Y; Tian C; Chen Y; Zou M; Han Y; Xu C; Ma S; Wang L; Wu X; Chen G; Wang Q
Transl Lung Cancer Res; 2021 Feb; 10(2):889-899. PubMed ID: 33718030
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
Liu Y; Hu X; Jiang J; Yang L; Zhou S; Liu P; Li J; Wang Y; Hao X; Shi Y
Oncologist; 2020 May; 25(5):e833-e842. PubMed ID: 32250517
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
9. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study.
Li H; Zeng J; Jin X; Yu X; Zhou G; Hong W
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1083-1090. PubMed ID: 30937519
[TBL] [Abstract][Full Text] [Related]
10. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
Xu Y; Huang Z; Lu H; Yu X; Li Y; Li W; Chen J; Chen M; Gong L; Chen K; Qin J; Xu X; Jin Y; Zhao J; Shi X; Han N; Xie F; Zhang P; Xu W; Fan Y
Br J Cancer; 2019 Oct; 121(8):640-646. PubMed ID: 31523058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
Yu W; Zhang H; Chen J; Zhang X; Chen Y; Qu G; Huang G; Zhou Y; Ye T; Fan Z; Yao Y
Ann Transl Med; 2022 Sep; 10(18):981. PubMed ID: 36267741
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
13. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
14. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Xu J; Liu X; Yang S; Shi Y
Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
[TBL] [Abstract][Full Text] [Related]
15. "Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study.
Wang M; Jiang H; Zhang M; Chen Y; Wang T; Li P
Dose Response; 2021; 19(4):15593258211055016. PubMed ID: 34790081
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
17. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy.
Ruan H; Dong J; Zhou X; Xiong J; Wang H; Zhong X; Cao X
Oncotarget; 2017 Nov; 8(61):104552-104559. PubMed ID: 29262660
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
Li Y; Sun Z; Sun W; Wang H; Zu J
Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
